Výsledky vyhledávání

Akademický článek

Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism.

Autor: Lee CA; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Oh DA; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Tang Y; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Yi P; Labcorp Drug Development, Madison, Wisconsin, USA., Bashir M; Labcorp Drug Development, Madison, Wisconsin, USA., English S; Pharmaron ABS, Inc, Germantown, Maryland, USA., Croft M; Pharmaron ABS, Inc, Germantown, Maryland, USA., Blackburn A; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Bloom S; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Gilder K; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA., Grundy JS; Arena Pharmaceuticals, Inc, San Diego, California, a wholly-owned subsidiary of Pfizer, Inc, New York, New York, USA.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jun; Vol. 12 (6), pp. 553-571. Date of Electronic Publication: 2023 May 03.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).

Autor: Chang L; David Geffen School of Medicine, UCLA, Los Angeles, California, USA., Cash BD; University of Texas Health Science Center Houston, Houston, Texas, USA., Lembo A; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Kunkel DC; University of California San Diego, La Jolla, California, USA., English BA; Arena Pharmaceuticals, Inc., San Diego, California, USA., Lindstrom B; Arena Pharmaceuticals, Inc., San Diego, California, USA., Gu G; Arena Pharmaceuticals, Inc., San Diego, California, USA., Skare S; Arena Pharmaceuticals, Inc., San Diego, California, USA., Gilder K; Arena Pharmaceuticals, Inc., San Diego, California, USA., Turner S; Arena Pharmaceuticals, Inc., San Diego, California, USA., Cataldi F; Arena Pharmaceuticals, Inc., San Diego, California, USA., Lipkis D; Sharp Grossmont Hospital, San Diego, California, USA., Tack J; University Hospitals Leuven, Leuven, Belgium.

Publikováno v: Neurogastroenterology and motility [Neurogastroenterol Motil] 2023 May; Vol. 35 (5), pp. e14539. Date of Electronic Publication: 2023 Feb 05.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion.

Autor: Halseth, A., Shan, K., Gilder, K., Malone, M., Acevedo, L., Fujioka, K.

Publikováno v: Obesity Science & Practice; Apr2018, Vol. 4 Issue 2, p141-152, 12p

Zobrazit plný text záznamu

Akademický článek

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review.

Autor: Tan, Wei-wei¹ (AUTHOR), Liu, Zi-xuan¹ (AUTHOR), Liu, Xiao-Yan¹ (AUTHOR), Zhang, Wei-bing¹ (AUTHOR), Zheng, Lie² (AUTHOR), Zhang, Ya-Li³ (AUTHOR), Dai, Yan-Cheng¹ (AUTHOR) daiyancheng2005@126.com

Publikováno v: Pain & Therapy. Dec2024, Vol. 13 Issue 6, p1447-1469. 23p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

P.750 Psychiatric- related safety of extended-release naltrexone/bupropion in combination with antidepressant therapy: Results from a large randomized controlled double-blind light trial

Autor: Blavignac, J., McIntyre S., R., McIntosh, D., Paron, E., Halseth, A., Gilder, K., Shan, K., Acevedo, L., Barakat, M.

Publikováno v: In European Neuropsychopharmacology December 2019 29 Supplement 6:S504-S504

Zobrazit plný text záznamu

Akademický článek

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.

Autor: Yacyshyn BR; Department of Gastroenterology, University of Cincinnati, Cincinnati, Ohio, USA., Hanauer S; Department of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA., Klassen P; Arena Pharmaceuticals Inc., Research and Development, San Diego, California, USA., English BA; Arena Pharmaceuticals Inc., Clinical Development, San Diego, California, USA., Stauber K; Arena Pharmaceuticals Inc., Nonclinical Development and Clinical Pharmacology, San Diego, California, USA., Barish CF; Department of Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Gilder K; Arena Pharmaceuticals Inc., Biostatistics and Data Management, San Diego, California, USA., Turner S; Arena Pharmaceuticals Inc., Olorinab Global Program Lead, San Diego, California, USA., Higgins PDR; Department of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.

Publikováno v: Crohn's & colitis 360 [Crohns Colitis 360] 2020 Oct 24; Vol. 3 (1), pp. otaa089. Date of Electronic Publication: 2020 Oct 24 (Print Publication: 2021).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání